The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...